Green-emitting carbon dot loaded silica nanoparticles coated with DNA-cross-linked hydrogels for sensitive carcinoembryonic antigen detection and effective targeted cancer therapy

2019 ◽  
Vol 55 (100) ◽  
pp. 15101-15104 ◽  
Author(s):  
Xiaoting Ji ◽  
Haoyuan Lv ◽  
Xinxin Sun ◽  
Caifeng Ding
Keyword(s):  
Drug Delivery ◽  
Cancer Therapy ◽  
Carcinoembryonic Antigen ◽  
Silica Nanoparticles ◽  
Targeted Drug Delivery ◽  
Antigen Detection ◽  
Targeted Cancer Therapy ◽  
Carbon Dot ◽  
Targeted Drug

Bifunctional composite nanospheres for carcinoembryonic antigen sensing and targeted drug delivery, based on carbon dot loaded silica nanoparticles coated with DNA-cross-linked hydrogels.

Biomolecules-conjugated nanomaterials for targeted cancer therapy

2014 ◽  
Vol 2 (48) ◽  
pp. 8452-8465 ◽  
Author(s):  
Jian Wang ◽  
Ting Ting Wang ◽  
Peng Fei Gao ◽  
Cheng Zhi Huang
Keyword(s):  
Drug Delivery ◽  
Cancer Therapy ◽  
Targeted Drug Delivery ◽  
Targeted Cancer Therapy ◽  
The Future ◽  
Targeted Drug

Now and in the future, with the development of artificial biomolecules as well as nanomaterials, targeted drug delivery based on elegant biomolecule–nanomaterial conjugation approaches is being developed to achieve great versatility, additional functions, and further advances.

A dual-responsive, hyaluronic acid targeted drug delivery system based on hollow mesoporous silica nanoparticles for cancer therapy

2018 ◽  
Vol 6 (28) ◽  
pp. 4618-4629 ◽  
Author(s):  
Lin Huang ◽  
Jia Liu ◽  
Fan Gao ◽  
Qian Cheng ◽  
Bo Lu ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Cancer Therapy ◽  
Mesoporous Silica ◽  
Silica Nanoparticles ◽  
Targeted Drug Delivery ◽  
Mesoporous Silica Nanoparticles ◽  
Dual Responsive ◽  
Targeted Drug ◽  
Hollow Mesoporous Silica ◽  
Targeted Drug Delivery System

A novel enzyme and redox dual-responsive targeted drug delivery system based on hollow mesoporous silica nanoparticles was developed for cancer therapy.

Lipid-based Nanoplatforms in Cancer Therapy: Recent Advances and Applications

2020 ◽  
Vol 20 (4) ◽  
pp. 271-287 ◽  
Author(s):  
Kuldeep Rajpoot
Keyword(s):  
Drug Delivery ◽  
Cancer Therapy ◽  
Adverse Effects ◽  
Targeted Drug Delivery ◽  
Tumor Therapy ◽  
Cancer Therapies ◽  
Medication Delivery ◽  
Lipid Nanocarriers ◽  
Targeted Drug ◽  
Drug Nanocarriers

Though modern available cancer therapies are effective, they possess major adverse effects, causing non-compliance to patients. Furthermore, the majority of the polymeric-based medication platforms are certainly not universally acceptable, due to their several restrictions. With this juxtaposition, lipid-based medication delivery systems have appeared as promising drug nanocarriers to replace the majority of the polymer-based products because they are in a position to reverse polymer as well as, drug-associated restrictions. Furthermore, the amalgamation of the basic principle of nanotechnology in designing lipid nanocarriers, which are the latest form of lipid carriers, has tremendous chemotherapeutic possibilities as tumor-targeted drug-delivery pertaining to tumor therapy. Apart from this, it is reported that nearly 40% of the modern medication entities are lipophilic. Moreover, research continues to be efficient in attaining a significant understanding of the absorption and bioavailability of the developed lipids systems.

scholarly journals ADAM9-Responsive Mesoporous Silica Nanoparticles for Targeted Drug Delivery in Pancreatic Cancer

Cancers ◽  
2021 ◽  
Vol 13 (13) ◽  
pp. 3321
Author(s):  
Etienne J. Slapak ◽  
Lily Kong ◽  
Mouad el Mandili ◽  
Rienk Nieuwland ◽  
Alexander Kros ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Mesoporous Silica ◽  
Silica Nanoparticles ◽  
Conditioned Medium ◽  
Drug Delivery System ◽  
Delivery System ◽  
Targeted Drug Delivery ◽  
Mesoporous Silica Nanoparticles ◽  
Pdac Cell ◽  
Targeted Drug

Pancreatic ductal adenocarcinoma (PDAC) has the worst survival rate of all cancers. This poor prognosis results from the lack of efficient systemic treatment regimens, demanding high-dose chemotherapy that causes severe side effects. To overcome dose-dependent toxicities, we explored the efficacy of targeted drug delivery using a protease-dependent drug-release system. To this end, we developed a PDAC-specific drug delivery system based on mesoporous silica nanoparticles (MSN) functionalized with an avidin–biotin gatekeeper system containing a protease linker that is specifically cleaved by tumor cells. Bioinformatic analysis identified ADAM9 as a PDAC-enriched protease, and PDAC cell-derived conditioned medium efficiently cleaved protease linkers containing ADAM9 substrates. Cleavage was PDAC specific as conditioned medium from leukocytes was unable to cleave the ADAM9 substrate. Protease linker-functionalized MSNs were efficiently capped with avidin, and cap removal was confirmed to occur in the presence of PDAC cell-derived ADAM9. Subsequent treatment of PDAC cells in vitro with paclitaxel-loaded MSNs indeed showed high cytotoxicity, whereas no cell death was observed in white blood cell-derived cell lines, confirming efficacy of the nanoparticle-mediated drug delivery system. Taken together, this research introduces a novel ADAM9-responsive, protease-dependent, drug delivery system for PDAC as a promising tool to reduce the cytotoxicity of systemic chemotherapy.

Protein Nanocarriers for Targeted Drug Delivery for Cancer Therapy

2019 ◽  
pp. 173-204 ◽  
Author(s):  
Mahadevappa Y. Kariduraganavar ◽  
Geetha B. Heggannavar ◽  
Sandra Amado ◽  
Geoffrey R. Mitchell
Keyword(s):  
Drug Delivery ◽  
Cancer Therapy ◽  
Targeted Drug Delivery ◽  
Targeted Drug

Targeted drug delivery for cancer therapy

2013 ◽  
pp. 31-56 ◽  
Author(s):  
D.L. Stirland ◽  
J.W. Nichols ◽  
T.A. Denison ◽  
Y.H. Bae
Keyword(s):  
Drug Delivery ◽  
Cancer Therapy ◽  
Targeted Drug Delivery ◽  
Targeted Drug
Sign in / Sign up

Export Citation Format

Share Document